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Summary
HFE-haemochromatosis is a genetic disorder  
resulting from mutations of the HFE gene. It  
primarily affects people of Northern European  
descent. Clinical manifestations result from the  
progressive deposition of iron into various organs 
including the liver. An elevated serum ferritin  
concentration greater than 300 microgram/L  
and a transferrin saturation of greater than  
45% will identify almost all patients with  
HFE-haemochromatosis. HFE genotyping confirms 
the diagnosis. In some patients, liver biopsy may 
still be necessary as the degree of hepatic fibrosis 
has prognostic implications.
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Introduction
HFe-haemochromatosis is the most frequent inherited cause 
of iron overload in humans. The condition is due to an inborn 
error of iron metabolism leading to inappropriately increased 
intestinal iron absorption. Its clinical manifestations result from 
progressive iron deposition in certain organs. It is important 
to identify individuals with HFe-haemochromatosis early in 
the course of their disease, as early intervention can prevent 
the development of complications. These include cirrhosis 
of the liver, cardiomyopathy, arthropathy and diabetes. Most 
patients are diagnosed following a presentation with nonspecific 
symptoms such as lethargy and fatigue, altered liver function 
tests, or a family history of haemochromatosis.
Genetics
The HFe gene is located on chromosome six. It codes for a 
cell surface protein which is involved in the regulation of iron 
metabolism. Mutations of the gene therefore disrupt normal 
iron metabolism. 
HFe-haemochromatosis is the most common autosomal 
recessive disorder in Northern european populations with 
heterozygous carrier rates of 1 in 10 and homozygosity rates of 
approximately 1 in 300. Homozygosity for the C282Y mutation 
accounts for 80–90% of cases of HFe-haemochromatosis 
and compound heterozygosity (C282Y/H63D) is the next 
most common genotype.1 Phenotypic expression is highly 
variable with only a minority of patients developing systemic 
complications of iron overload. 
An Australian study of people of Northern european descent 
reported symptoms and signs of iron overload in 28.4% of 
males and 1.2% of females who were C282Y homozygous.2 
The same study found that symptomatic iron overload was rare 
among compound heterozygotes (0.2%). 
Transferrin saturation
The first approach to diagnosing HFe-haemochromatosis is the 
assessment of indirect markers of iron stores. Fasting transferrin 
saturation is considered to be the most sensitive screening test 
for HFe-haemochromatosis. 
An elevated fasting transferrin saturation greater than 50% 
in women and 60% in men of Northern european descent 
has a positive predictive value of 86% for the diagnosis of 
HFe-haemochromatosis.3 Lowering the threshold transferrin 
saturation to 45% improves the sensitivity and negative 
predictive value, but reduces the positive predictive value. 
In an Australian population study, a value of 45% was able 
to correctly identify 98% of C282Y homozygotes.4 However, 
using this value will also detect heterozygotes who do not 
need further investigations. Approximately 30% of C282Y 
heterozygotes have a transferrin saturation greater than 45%. 
The combination of an elevated fasting transferrin saturation 
(greater than 45%) and an elevated serum ferritin has a negative 
predictive value of 97%. This exceeds the accuracy of either test 
used alone.3
Serum ferritin concentration
Raised serum concentrations of ferritin occur in a number of 
different conditions including iron overload. There are also 
several causes of iron overload (see box). In the setting of iron 
overload, the serum ferritin tends to reflect total body iron 
stores and generally increases with progressive iron loading.5 
Abnormal laboratory results
74 | VoLUME 34 | NUMBEr 3 | JUNE 2011 www.austral ianprescriber.com
An Australian population-based study reported a sensitivity of 
50% and specificity of 87% for serum ferritin concentrations 
greater than 300 microgram/L for the diagnosis of C282Y 
homozygosity.6 Higher serum ferritin thresholds have been 
studied in an attempt to lower the rate of false positives and 
increase the positive predictive value for the detection of  
HFe-haemochromatosis. For example, a population-based study 
screening 29 699 people identified 59 patients with a serum 
ferritin concentration greater than 1000 microgram/L, of whom 
24 had HFe-haemochromatosis with 20 people being C282Y 
homozygous.7 
Serum ferritin concentrations greater than 1000 microgram/L 
are associated with a higher risk of cirrhosis and may be 
used as an indication for liver biopsy.8 A French study 
reported a sensitivity of 98%, a specificity of 72% and a 
positive predictive value of 55% when using a serum ferritin 
concentration of 1000 microgram/L to predict the presence 
of severe fibrosis among C282Y homozygotes.9 Similar 
findings have been reported in Australian and Canadian 
populations.10,11 other factors that increase the clinical 
probability of severe fibrosis include hepatomegaly, abnormal 
transaminase levels, age greater than 35 years and a history 
of excessive alcohol intake.
An isolated elevated serum ferritin is often seen with acute or 
chronic inflammation. Patients with an isolated elevated serum 
ferritin should therefore be evaluated for other causes before 
genetic testing is considered.12 More than 90% of people in the 
general community who have an elevated serum ferritin will 
have one of the following diagnoses:
■■ systemic inflammation
■■ chronic alcohol consumption
■■ non-alcoholic fatty liver disease
■■ hepatocellular necrosis
■■ malignancy.
In these clinical conditions, serum ferritin concentration is 
usually less than 1000 microgram/L and is often accompanied 
by a normal transferrin saturation. This is a common clinical 
scenario and interpretation of these patients' iron studies 
is often compounded by the presence of heterozygosity 
for the HFe mutations. Despite the elevated serum ferritin 
concentration, the vast majority of these patients do not have 
significant iron overload and treatment of the underlying 
condition usually results in a decrease in the serum ferritin 
concentration. Moreover, serum ferritin concentration increases 
with age and is influenced by gender and physiological blood 
loss. Interpretation of serum ferritin concentration requires 
careful consideration of these characteristics in each patient.
Measuring C-reactive protein may help to exclude systemic 
inflammation if it is not clinically evident. other tests such as 
serum aspartate transaminase, alanine transaminase, creatinine 
kinase, erythrocyte sedimentation rate, fasting glucose, and the 
lipid profile may also help to exclude other causes of an isolated 
elevated serum ferritin.
HFE genotyping
The diagnostic evaluation of people with suspected  
HFe-haemochromatosis changed following the discovery 
of the HFe gene in 1996.1 Blood tests for HFe genotyping 
should be considered in people with suspected iron overload, 
patients with a family history of HFe-haemochromatosis and 
cases of unexplained chronic liver disease with an increased 
transferrin saturation12 (see Fig. 1). Genetic screening for 
HFe-haemochromatosis in the general population is not 
recommended because the disease penetrance is low.12
Most patients with HFe-haemochromatosis are C282Y 
homozygotes and the majority of the remaining cases are 
compound heterozygotes (C282Y/H63D). H63D homozygosity 
does not result in significant hepatic iron overload and an 
elevated serum ferritin in these patients is usually the result of 
hepatic steatosis or excess alcohol consumption.13 
other tests
Following the advent of HFe genotyping, liver biopsy  
is no longer necessary to make a diagnosis of HFe- 
haemochromatosis. However, liver biopsy is still required 
to stage hepatic fibrosis, especially as patients with serum 
ferritin concentrations greater than 1000 microgram/L are more 
likely to have cirrhosis.9 Diagnosing the presence of cirrhosis 
in HFe-haemochromatosis is clinically important as affected 
patients have a significant risk of hepatocellular carcinoma and 
should enter a surveillance program. When the diagnosis of 
Box
Causes of iron overload
Hereditary haemochromatosis
■■ HFe-haemochromatosis
■■ non-HFe-haemochromatosis
Secondary iron overload
■■ multiple blood transfusions
■■ iron-loading anaemia (β-thalassaemia and sideroblastic 
anaemia)
Chronic liver disease
■■ hepatitis C infection
■■ alcohol-related liver disease
■■ non-alcoholic fatty liver disease
■■ porphyria cutanea tarda
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iron overload remains unclear, liver biopsy or MRI may still be 
required to assess for hepatic iron overload. 
The special form of MRI is a non-invasive method of directly 
assessing hepatic iron concentration. There is an excellent 
inverse correlation between the signalling and hepatic iron 
concentration.14 The main limitation of this method is its 
inability to stage hepatic fibrosis. Transient elastography, a 
special form of ultrasound, may have a role in staging fibrosis 
as an alternative to liver biopsy.15
Family screening 
Siblings of patients with HFe-haemochromatosis should 
undergo HFe genotyping as they have a 25% chance of being 
affected.12 In clinical practice, most family members also have 
serum iron indices measured to assess their body iron stores. 
Whether individuals are screened depends upon several factors 
including their age and health status, and the attitudes of the 
family.12 In the case of children who have a parent with  
HFe-haemochromatosis, HFe genotyping of the unaffected 
Fig. 1
Algorithm for the diagnosis and management of HFE-haemochromatosis
elevated serum ferritin +  
transferrin saturation >45%
C282Y/H63D or  
C282Y/wild-type or  
non-HFe genotype
Serum ferritin <1000 microgram/L
No cirrhosis
Venesection and family screening
Consider other causes of chronic liver  
disease and refer for specialist evaluation
Check HFe genotype
Serum ferritin >1000 microgram/L
C282Y/C282Y
Cirrhosis
Diagnosis of  
HFE-haemochromatosis confirmed
Refer for consideration of liver biopsy to 
determine extent of fibrosis
Venesection, family screening and 
hepatocellular carcinoma surveillance
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parent may be of value.16 In such cases, the likelihood of genetic 
susceptibility and the need for testing of children later in life can 
be established.
Conclusion
HFe-haemochromatosis is a common genetic disorder 
primarily affecting people of North european descent. early 
diagnosis and treatment prevent progressive disease. It is 
important that people with characteristics associated with 
severe hepatic fibrosis or cirrhosis are identified and managed 
appropriately.
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recommendations
■■ Patients with suspected iron overload should first have 
their serum ferritin and fasting transferrin saturation 
measured.
■■ HFe genotyping should be carried out in all patients with 
an elevated serum ferritin and transferrin saturation.
■■ Diagnosis of HFe-haemochromatosis should not be based 
on C282Y homozygosity alone, but requires evidence 
of increased hepatic iron stores. People who are C282Y 
homozygotes with normal iron stores should undergo 
regular testing.
■■ Compound heterozygotes (C282Y/H63D) and H63D 
homozygotes presenting with an elevated serum ferritin 
should first be investigated for other causes of an elevated 
serum ferritin, in particular alcohol and non-alcoholic fatty 
liver disease. 
■■ Liver biopsy should be offered to C282Y homozygotes 
with a serum ferritin greater than 1000 microgram/L as 
these patients are at risk of cirrhosis. 
■■ As HFe-haemochromatosis is an autosomal recessive 
disease, genetic testing of siblings and other first degree 
family members is recommended.
Self-test questions
The following statements are either true or false  
(answers on page 91)
3. The diagnosis of HFe-haemochromatosis requires a 
liver biopsy.
4. HFe-haemochromatosis is the most common cause of 
an isolated elevation of serum ferritin.
